home / stock / abus / abus quote
Last: | $2.73 |
---|---|
Change Percent: | -0.73% |
Open: | $2.74 |
Close: | $2.75 |
High: | $2.75 |
Low: | $2.68 |
Volume: | 187,438 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.73 | $2.74 | $2.75 | $2.75 | $2.68 | 187,438 | 04-25-2024 |
$2.75 | $2.75 | $2.75 | $2.78 | $2.735 | 344,844 | 04-24-2024 |
$2.75 | $2.64 | $2.75 | $2.75 | $2.64 | 1,088,913 | 04-23-2024 |
$2.64 | $2.73 | $2.64 | $2.765 | $2.635 | 740,415 | 04-22-2024 |
$2.72 | $2.71 | $2.72 | $2.81 | $2.65 | 931,457 | 04-19-2024 |
$2.73 | $2.78 | $2.73 | $2.8 | $2.69 | 1,016,821 | 04-18-2024 |
$2.78 | $2.91 | $2.78 | $2.9377 | $2.78 | 710,512 | 04-17-2024 |
$2.92 | $2.94 | $2.92 | $2.94 | $2.88 | 644,013 | 04-16-2024 |
$2.97 | $2.9 | $2.97 | $2.99 | $2.82 | 3,626,020 | 04-15-2024 |
$2.91 | $2.99 | $2.91 | $3.03 | $2.9 | 666,195 | 04-12-2024 |
$3.03 | $2.95 | $3.03 | $3.05 | $2.94 | 860,344 | 04-11-2024 |
$2.98 | $3.01 | $2.98 | $3.02 | $2.9 | 1,113,726 | 04-10-2024 |
$3.005 | $3.06 | $3.005 | $3.11 | $3 | 798,622 | 04-09-2024 |
$3.09 | $3.17 | $3.09 | $3.185 | $3.03 | 1,225,524 | 04-08-2024 |
$3.12 | $3.02 | $3.12 | $3.29 | $2.98 | 6,083,303 | 04-05-2024 |
$3 | $2.93 | $3 | $3.11 | $2.86 | 8,084,294 | 04-04-2024 |
$2.92 | $2.51 | $2.92 | $3.25 | $2.3 | 12,477,255 | 04-03-2024 |
$2.52 | $2.52 | $2.52 | $2.5373 | $2.485 | 450,651 | 04-02-2024 |
$2.56 | $2.61 | $2.56 | $2.61 | $2.545 | 486,654 | 04-01-2024 |
$2.58 | $2.59 | $2.58 | $2.61 | $2.55 | 525,829 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leve...
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it...